AUTOCYTE PREP AUTOMATED SAMPLE PREPARATION SYSTEM PMA FILED JUNE 11, FIRM SAYS IN INITIAL PUBLIC OFFERING; SCREEN PMA SLATED FOR LATE `97, EARLY `98
This article was originally published in The Gray Sheet
Executive SummaryAutocyte plans to use a portion of proceeds from its $36.6 mil. initial public offering to nearly triple the size of its sales and marketing organization in anticipation of U.S. and international launches of the Prep automated cervical specimen preparation device and Screen automated slide screening and interpretation system, the Burlington, North Carolina-based firm says in a June 27 preliminary prospectus for the IPO.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.